Richard Waldron
Director of Finance/CFO bij BIOATLA, INC.
Vermogen: 794 375 $ op 31-03-2024
Profiel
Richard A.
Waldron's current job(s) include being a Director at Himalaya Therapeutics and Chief Financial & Accounting Officer at BioAtla, Inc. Mr. Waldron's former job(s) include being a Managing Director at Rauscher Pierce Refsnes, Inc. from 1990 to 1995, Chief Financial Officer, Secretary & Executive VP at SciClone Pharmaceuticals LLC from 2001 to 2008, Chief Financial Officer & Vice President at gMed., Inc., Chief Financial Officer at Genelabs Technologies, Inc. from 1999 to 2000, and CFO-Protein Production Division at Precigen, Inc. from 2009 to 2010.
Mr. Waldron's education history includes an undergraduate degree from Princeton University and an undergraduate degree from Harvard Business School.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
BIOATLA, INC.
0.48% | 15-02-2024 | 230 923 ( 0.48% ) | 794 375 $ | 31-03-2024 |
Actieve functies van Richard Waldron
| Bedrijven | Functie | Begin |
|---|---|---|
| BIOATLA, INC. | Director of Finance/CFO | 01-11-2013 |
Himalaya Therapeutics
 Himalaya Therapeutics Medical/Nursing ServicesHealth Services Himalaya Therapeutics is a Caymanian clinical-stage biotechnology company that is advancing its pipeline of novel monoclonal antibody and other protein therapeutic product candidates through clinical trials. The company is based in George Town, Cayman Islands, with operations in Taiwan and China. The company's product candidates have been developed using cab technology, which is protected by more than 500 issued and pending patents. Himalaya has two cab programs currently in phase 2 clinical testing in Taiwan\: BA3011, a novel conditionally active AXL-targeted antibody-drug conjugate (CAB-AXL-ADC), and BA3021, a novel conditionally active ROR2-targeted antibody-drug conjugate (CAB-ROR2-ADC). Himalaya has a co-development and collaboration agreement for an investigational CAB CTLA-4 antibody, BA3071, with BeiGene Ltd. for its development, manufacturing, and commercialization in Greater China. The company was founded by Carolyn Anderson Short and Jay M. Short, and the CEO is Brian Zhang. | Director/Board Member | - |
Eerdere bekende functies van Richard Waldron
| Bedrijven | Functie | Einde |
|---|---|---|
| PRECIGEN, INC. | Corporate Officer/Principal | 01-12-2010 |
| SCICLONE PHARMACEUTICALS, INC. | Director of Finance/CFO | 04-04-2008 |
gMed., Inc.
 gMed., Inc. BiotechnologyHealth Technology gMed is engaged in providing physicians with information solutions to “Care Better” for their patients and practice. The company provides Digital Charting solutions for Gastroenterology and Cardiology designed to eliminate paper, increase revenues, decrease costs and enhance patient care at the medical office, ambulatory surgery center and hosptial. gMED was founded in 1997 and is located in Weston, FL. | Director of Finance/CFO | 14-09-2006 |
Genelabs Technologies, Inc.
 Genelabs Technologies, Inc. Pharmaceuticals: MajorHealth Technology Genelabs Technologies, Inc. discovery and development of pharmaceutical products to improve human health. The company was founded by Brian D. Frenzel and Frank C. Kung in 1983 and is headquartered in Redwood, CA. | Director of Finance/CFO | 01-08-2000 |
| Rauscher Pierce Refsnes, Inc. | Corporate Officer/Principal | 01-07-1995 |
Opleiding van Richard Waldron
| Princeton University | Undergraduate Degree |
| Harvard Business School | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| PRECIGEN, INC. | Health Technology |
| BIOATLA, INC. | Health Technology |
| Bedrijven in privébezit | 5 |
|---|---|
SciClone Pharmaceuticals LLC
 SciClone Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology SciClone Pharmaceuticals LLC was engaged in the development of therapeutic treatment for oncology, infectious diseases, and cardiovascular disorders. It was also offering ZADAXIN for the treatment of hepatitis B, hepatitis C, certain cancers, and used as immune system enhancer, and DC Bead which is used for the novel treatment of liver cancer. The company was founded in 1990 and was headquartered in San Mateo, CA. | Health Technology |
gMed., Inc.
gMed., Inc. BiotechnologyHealth Technology gMed is engaged in providing physicians with information solutions to “Care Better” for their patients and practice. The company provides Digital Charting solutions for Gastroenterology and Cardiology designed to eliminate paper, increase revenues, decrease costs and enhance patient care at the medical office, ambulatory surgery center and hosptial. gMED was founded in 1997 and is located in Weston, FL. | Health Technology |
Genelabs Technologies, Inc.
Genelabs Technologies, Inc. Pharmaceuticals: MajorHealth Technology Genelabs Technologies, Inc. discovery and development of pharmaceutical products to improve human health. The company was founded by Brian D. Frenzel and Frank C. Kung in 1983 and is headquartered in Redwood, CA. | Health Technology |
| Rauscher Pierce Refsnes, Inc. | Finance |
Himalaya Therapeutics
Himalaya Therapeutics Medical/Nursing ServicesHealth Services Himalaya Therapeutics is a Caymanian clinical-stage biotechnology company that is advancing its pipeline of novel monoclonal antibody and other protein therapeutic product candidates through clinical trials. The company is based in George Town, Cayman Islands, with operations in Taiwan and China. The company's product candidates have been developed using cab technology, which is protected by more than 500 issued and pending patents. Himalaya has two cab programs currently in phase 2 clinical testing in Taiwan\: BA3011, a novel conditionally active AXL-targeted antibody-drug conjugate (CAB-AXL-ADC), and BA3021, a novel conditionally active ROR2-targeted antibody-drug conjugate (CAB-ROR2-ADC). Himalaya has a co-development and collaboration agreement for an investigational CAB CTLA-4 antibody, BA3071, with BeiGene Ltd. for its development, manufacturing, and commercialization in Greater China. The company was founded by Carolyn Anderson Short and Jay M. Short, and the CEO is Brian Zhang. | Health Services |
